Article by Harrison Jordan, Lift News
Canada has one stringent commercial medical cannabis program, requiring its licensed producers to implement standard operating procedures, good manufacturing processes and rigorous quality assurance and control.
Some might argue the Access to Cannabis for Medical Purposes Regulations (ACMPR) have resulted in recalls for some rather innocuous errors, but when it comes to treating various medical ailments, it’s crucial accurate and reliable information is communicated to patients.
Here are four medical marijuana recalls that demonstrate that Health Canada does not mess around when it comes to labelling, accurate THC and CBD indicators and testing for illegal pesticides.
- Where’s the per cent symbol? Most recently (and 2018’s first) Canadian licensed producer Aphria announced a Type III recall in early January because the labels on the containers of cannabis omitted a per cent sign (%) next to the numerical content for THC and CBD. While THC and CBD content is important for medical cannabis users to know for dosing purposes, Type III recalls are undertaken when a product is not likely to cause any adverse health consequences.